The Gen XY Lifestyle
Winlevi® Lands in Southeast Asia: Acne Treatment For Singapore and Malaysia
If you’ve battled acne and felt let down by decades-old options, Hyphens Pharma has some news that might change the game.
The Singapore-based specialty pharmaceutical group has officially launched Winlevi® (clascoterone) cream 1% in Singapore and Malaysia—marking the first time this innovative topical treatment is available in Southeast Asia. With a bold promise to tackle acne through a novel mechanism of action, Winlevi® targets the androgen-sebum pathway right within the skin, making it a standout in a field that hasn’t seen new molecular classes for over four decades.
Unlike oral anti-androgens or systemic treatments with potential hormonal side effects, Winlevi® acts locally, making it suitable for both male and female patients. By reducing sebum production and inflammation while avoiding systemic disruption, it offers a smarter, safer solution for doctors and patients alike.
Winlevi® is the first commercial topical androgen receptor inhibitor for acne, backed by global traction with over 1.3 million prescriptions in the US since its debut in 2021.
Clinical Confidence Meets Community Impact
To guide the roll-out across clinics and hospitals, Hyphens Pharma convened a multinational Advisory Board of 12 leading dermatologists from Singapore, Malaysia, the Philippines, and the US. Their goal? To integrate Winlevi® into everyday practice by delivering real-world insights and support for doctors.
More importantly, the company is taking acne seriously—not just as a skin condition, but as one with real psychosocial impact. As Executive Chairman and CEO Lim See Wah put it, “Acne isn’t just skin-deep. By expanding access to Winlevi®, we aim to support doctors in their practice and empower patients to manage acne with greater confidence, improving their quality of life.”
Hyphens Pharma plans a progressive rollout across other Southeast Asian markets including Indonesia, Thailand, the Philippines, and Vietnam. With market registration underway, patients across the region could soon have access to a treatment that reshapes how acne is approached.
